Savient Announces Krystexxatm Resubmitted Bla Accepted For Review By The Fda
Posted by admin | Posted in Uncategorized | Posted on 27-01-2012-05-2008
0
Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of and accepted for review the March 15, 2010 resubmission of the Biologics License Application (BLA) for KRYSTEXXAâ„ (pegloticase), a treatment for chronic gout in patients refractory to conventional therapy…
Original post: Savient Announces KRYSTEXXA(TM) Resubmitted BLA Accepted For Review By The FDA